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Abstract: We aimed to review and synthesize results reporting on the maintenance efficacy of 
Aripiprazole in adults with bipolar I disorder. Aripiprazole is FDA approved for the acute and 
maintenance treatment of bipolar I disorder. Aripiprazole’s efficacy during the long-term treat-
ment of bipolar disorder is supported by extension of acute phase studies and long-term (ie, 100-
week) double-blind placebo controlled recurrence prevention registration trials. Aripiprazole 
is not established as efficacious in the acute or maintenance treatment of bipolar depression. 
Moreover, aripiprazole’s efficacy during the acute or maintenance phase of   bipolar II disorder 
has not been sufficiently studied. Aripiprazole has a relatively lower hazard for metabolic disrup-
tion and change in body composition when compared to other atypical agents (eg, olanzapine, 
quetiapine). Moreover, aripiprazole has minimal propensity for sedation, somnolence and pro-
lactin elevation. Aripiprazole is associated with extrapyramidal side effects, notably akathisia, 
which in most cases is not severe or treatment limiting. Future research vistas are to explore 
aripiprazole’s efficacy in bipolar subgroups; recurrence prevention of bipolar depression; and 
in combination with other mood stabilizing agents.
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Introduction
During the past decade, the US FDA has approved several agents for the maintenance 
treatment of bipolar disorder (BD). Aripiprazole is approved as monotherapy and 
adjunctive treatment for the acute and maintenance treatment of adults with bipolar I 
disorder and for the treatment of pediatric mania. Several reviews have been published 
by ourselves and other groups pertinent to aripiprazole’s efficacy in bipolar mania and 
depression and will not be reviewed herein.1 Increasingly, the therapeutic emphasis in 
BD has been on the maintenance phase, largely due to increased recognition of the ill-
ness burden attributable to BD. Moreover, the long-term hazards of many psychotropic 
agents on body composition and metabolic parameters have differentiated aripiprazole 
as an alternative with a lower propensity toward adverse metabolic outcomes.
Methods
We conducted a PubMed search of all English-language articles published between 
January 1995 and January 2011. The key search term was aripiprazole combined with: 
randomized controlled trials, pharmacology, pharmacokinetics, pharmacodynamics, 
depression, mania, maintenance and BD. The search was augmented with a manual 
review of relevant article reference lists. We delimited our review to pivotal mainte-
nance randomized controlled registration trials in BD.Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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Aripiprazole: pharmacokinetics/
pharmacodynamics
Pharmacokinetics
Aripiprazole is available in oral compressed tablet, oral 
disintegrating tablet, non-refrigerated oral solution, and intra-
muscular formulations.2 Aripiprazole tablets are available in 
2-, 5-, 10-, 15-, 20- and 30-mg strengths. The effective dose 
range for patients with bipolar I disorder is between 15 and 
30 mg/day. Orally disintegrating tablets are available in 10 mg 
and 15 mg strengths. In addition, aripiprazole is available 
in a 1 mg/mL non-refrigerated oral solution. Parenteral 
aripiprazole is intended for intramuscular use only and is 
available in several 7.5 mg/mL doses (ie, 5.25 mg/0.7 mL, 
9.75 mg/1.3 mL, and 15 mg/2 mL) of clear, colorless, ster-
ile, aqueous solution.3 The oral formulation of aripiprazole 
is indicated for the acute and maintenance treatment of 
schizophrenia and BD, whereas the parenteral formulation 
is indicated for agitation associated with schizophrenia or 
bipolar mania.
The compressed tablets are extensively absorbed through 
the gastrointestinal tract with a bioavailability of 87%. The 
time to peak plasma concentration (Tmax) is 3–5 hours for 
aripiprazole; food intake does not significantly affect peak 
plasma concentration (Cmax) but may delay Tmax.4   Aripiprazole 
exhibits linear pharmacokinetics between the dosing ranges 
of 5–30 mg/day. At equivalent doses (ie, 30 mg/day), the 
plasma concentration of aripiprazole oral solution was higher 
than that of the compressed tablet, ie, the solution-to-tablet 
ratio of geometric Cmax and area under concentration-time 
curve (AUC) values were 122% and 114%. Aripiprazole oral 
disintegrating tablets are bioequivalent to the compressed 
tablets. The time to peak plasma concentration with aripip-
razole injection is 1–3 hours and has an absolute bioavail-
ability of 100%. The geometric mean Cmax achieved after an 
intramuscular (IM) dose was approximately 19% higher than 
the Cmax of the oral tablet; the aripiprazole AUC in the first 
2 hours after the initial IM injection is 90% greater than the 
AUC after a similar tablet dose. Over 24 hours of dosing, the 
systemic exposure is similar between aripiprazole injection 
and oral tablet administration.3
The half-life of aripiprazole is longer than other atypical 
agents, ie, 48–75 hours for aripiprazole and 94 hours for the 
active principal metabolite, dehydroaripiprazole. Steady state 
with aripiprazole is achieved within 14 days of administra-
tion.4 The volume of distribution of aripiprazole is 404 L 
(4.9 L/kg) and it is extensively bound to plasma proteins 
(99%). Aripiprazole is metabolized mainly in the liver via the 
cytochrome P450 (CYP) enzymes 3A4 and 2D6, primarily 
via   dehydrogenation, hydroxylation and N-dealkylation.4 
Approximately 40% of aripiprazole AUC in plasma is com-
prised of dehydroaripiprazole. Slow metabolizers at CYP3A4 
or CYP2D6 exhibit an increase in Cmax ie, an 80% increase in 
aripiprazole exposure and 30% decrease in active metabolite 
exposure and half-life (ie, 146 hours versus 48–75 hours) and 
will require adjustment of dosing.4 Excretion of aripiprazole 
occurs via the kidney and liver with 25% and 55% of the dose 
recovered in the urine and feces respectively.2,4
Aripiprazole does not induce or inhibit CYP enzymes 
3A4 and 2D6. Aripiprazole does not alter the pharmacokinet-
ics of divalproex sodium or lithium and vice versa. Although 
renal and hepatic impairment results in an increase in Cmax, 
dosage adjustment is not required. Although Cmax and AUC 
is 30% and 40% higher respectively in women than men, no 
dosing adjustment is necessary.2,4
Pharmacodynamics
Aripiprazole is a highly lipid soluble quinolone-derived 
novel psychotropic agent.5,6 Aripiprazole’s receptor profile 
has been well characterized pre-clinically in vitro and in 
vivo.7   Aripiprazole exhibits high receptor affinity for D2 
and D3 receptors with moderate affinity for D4 receptors. 
Aripiprazole acts as a partial agonist at the pre-synaptic dop-
amine autoreceptors and post-synaptic D2 receptors (where 
it may have a higher intrinsic activity).8,9 This in vitro profile 
provides for functional antagonism in hyperdopaminergic 
states and functional agonism in hypodopaminergic states.10 
Dehydroaripiprazole, has similar pharmacodynamic effects 
at the D2 receptors.7
Aripiprazole exhibits high affinity for 5-HT1A and 5-HT2A 
receptors, resulting in partial agonism and antagonism 
respectively. The partial agonism at the 5-HT1A receptor 
is similar to the anxiolytic azapirones.11 Aripiprazole is an 
inverse agonist at 5-HT2B receptors and a partial agonist at 
5-HT2C, 5-HT7, D3 and D4 receptors. Aripiprazole displays 
low affinity for H1-histaminergic, muscarinic, cholinergic, 
and adrenergic receptors. This profile is predictive of low 
propensity to extrapyramidal symptoms (EPS), weight-gain, 
metabolic disruption, hyperprolactinemia and sedation.12
Aripiprazole: maintenance 
treatment in bipolar disorder
A single randomized, double-blind parallel group placebo-
  controlled study reported on the safety and efficacy of 
aripiprazole in preventing relapse of a mood episode in   
recently manic, or mixed episode patients with bipolar I dis-
order stabilized with aripiprazole.13–15 This multiphase study Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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began with an open-label stabilization phase followed by a 
double-blind phase that extended to 100 weeks.
During the stabilization phase, patients received open-
label treatment with aripiprazole 15 or 30 mg/day for 
6–18 weeks. Patients meeting stabilization criteria [ie, 
Young Mania Rating Scale (YMRS) total score #10 and 
  Montgomery Asberg Depression Rating Scale (MADRS) 
total score of #13 during 4 consecutive visits over a mini-
mum of 6 weeks] were eligible for the double-blind phase in 
which they were randomized to the aripiprazole dose received 
at the end of the stabilization phase or placebo.
The primary efficacy parameter was time to relapse for 
a mood episode (ie, manic, depressive or mixed) during the 
double-blind phase. Relapse was defined by discontinua-
tion due to inefficacy (ie, hospital admission due to mood 
episode), and/or addition to or increase in psychotropic 
medication other than study drug for manic and/or depres-
sive symptoms. Secondary efficacy parameters were time to 
manic and depressive relapse and change from randomiza-
tion to endpoint on continuous efficacy metrics [ie, YMRS, 
MADRS, Clinical Global Impression for use in bipolar 
illness (CGI-BP), and Positive and Negative Syndrome 
Scale (PANSS) total score as well as cognitive and hostility 
subscales].
Five hundred and sixty-seven patients entered the stabi-
lization phase, which included 333 who had participated in 
earlier studies of aripiprazole. Of the total, 206 completed the 
stabilization phase, 161 entered the double-blind phase and 
67 completed the double-blind phase. At 26 weeks, the mean 
aripiprazole dose was 24.3 mg/day. Most patients (71%) in 
both groups required at least one concomitant medication. 
Time to relapse was significantly longer for aripiprazole-
treated patients than for placebo-treated patients (P = 0.02). 
The mean change from baseline to end-point in YMRS total 
score, PANSS cognitive subscale score and CGI-BP sever-
ity was superior in the aripiprazole-treated group compared 
to placebo.
More patients receiving placebo discontinued the study 
prematurely due to treatment emergent adverse events 
(TEAE) (19%) versus aripiprazole (10%). The five most 
commonly reported TEAEs ($5%) in the aripiprazole-treated 
group were anxiety (17%), insomnia (16%), depression 
(12%), nervousness (10%), and tremor (9%). For placebo, 
the most commonly reported TEAEs were insomnia (19%), 
headache (17%), anxiety (15%), depression (15%), and 
manic reaction (13%). The rates of EPS were higher in the 
aripiprazole group; tremor was the most frequently reported 
EPS. A higher percentage of patients receiving aripiprazole 
had significant elevation of Simpson Angus Scale (SAS) and 
Barnes Akathisia Rating Scale (BARS) total scores.
Mean weight change from randomization to endpoint 
was -1.7+/-0.8 kg and +0.5+/-0.8 kg for placebo and arip-
iprazole, respectively. At the end of 26 weeks of treatment, 
significant weight-gain was observed in 13% of the aripipra-
zole treated patients and none of the placebo-treated patients. 
Aripiprazole-treated patients exhibited a non-significant 
decrease in mean serum prolactin concentration from ran-
domization to end-point. No significant changes were noted 
in vital signs, corrected QT interval (QTc), fasting glucose, 
high-density lipoprotein (HDL), or low-density lipoprotein 
(LDL) concentration.
A 74-week extension study, which included the cohort 
from the 26-week study, was subsequently published. The 
inclusion and exclusion criteria of the extension study as 
weel as its definition of relapse were identical to the 26-week 
double-blind phase. In total, of the 67 patients who com-
pleted the initial 26-week double-blind phase, 66 entered 
the 74-week extension phase. During the 74-week extension, 
there were more discontinuations due to lack of efficacy from 
the placebo group (26%) than the aripiprazole group (13%). 
The mean aripiprazole dose during the combined 26-week 
and 74-week double-blind phases was 24.1 mg/day.
Time to relapse into any mood episode during double-
blind treatment was significantly longer for patients who 
received aripiprazole than placebo. Time to manic relapse 
was significantly longer for aripiprazole treated than pla-
cebo treated patients. There were no differences in time to 
depressive relapses between groups. The mean change in 
YMRS total score from baseline of the double-blind phase 
to week 100 was significantly greater in the placebo versus 
the aripiprazole group. There were no differences between 
groups from baseline to week 100 in the total MADRS score. 
Improvements on the PANSS cognitive subscale score and 
PANSS hostility subscale were significantly greater for 
aripiprazole. The mean change from baseline to week 100 in 
the CGI-BP severity illness score was greater in aripiprazole 
treated subjects.
Adverse events related to EPS occurred more   frequently 
with aripiprazole compared to placebo (22% versus 
15%). The most common EPS were tremor (9% versus 1%), 
akathisia (8% versus 1%), and hypertonia (4% versus 2%). 
Mean change from baseline of the double-blind phase to week 
100 on the SAS, AIMS, and BARS were not significantly dif-
ferent between groups. The mean weight change in patients 
treated with placebo was -1.9 ± 0.8 kg and 0.4 ± 0.8 kg with 
aripiprazole.Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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A separate randomized double-blind active agent and 
placebo-controlled study compared long-term efficacy and 
tolerability of aripiprazole with lithium monotherapy in 
the acute and maintenance treatment of bipolar I disorder.17 
Patients with acute bipolar mania or mixed states who required 
hospitalization were randomized to receive aripiprazole 
15–30 mg/day, lithium 900–1500 mg or placebo for 3 weeks. 
At the completion of 3 weeks, those who had been randomized 
to placebo during the 3 week phase were blindly switched to 
aripiprazole whereas aripiprazole- and lithium-treated patients 
continued with their assigned treatment.
All patients continued double-blind treatment to week 12 at 
which time they could enter a 40-week double-blind extension 
phase. At week 12, 27%, 34%, and 29% of subjects receiv-
ing aripiprazole, lithium or placebo respectively completed 
the treatment. Improvement in mean YMRS total score was 
significantly greater with aripiprazole compared with placebo 
beginning at day 2 and extending to week 3. Lithium was asso-
ciated with significant improvement compared to placebo at 
week 3. The most commonly encountered TEAEs with aripip-
razole and lithium were headache (23% and 22% respectively), 
nausea (23% and 24%), akathisia (15% and 5%), sedation 
(13% and 7%), constipation (10% and 13%), and tremor (8% 
and 12%). There were no differences between aripiprazole and 
lithium treated subjects in total weight gain.
A separate 46-week open-label study evaluated the 
maintenance efficacy of aripiprazole in combination with 
lithium or valproate in the treatment of adults with BD.18 This 
46-week study represented an extension of a previous 6-week 
study evaluating the combination of aripiprazole with lithium 
or divalproex.19 Patients with bipolar mania or mixed states 
with a partial non-response to lithium/  valproate monotherapy 
(ie, YMRS total score $16 after at least 2 weeks of lithium/
valproate monotherapy) were eligible for enrolment to receive 
either aripiprazole 15 or 30 mg or placebo for 6 weeks.
Efficacy was assessed by the mean change in the YMRS and 
MADRS total scores from the end of the 6-week double-blind 
phase to week 46. Of the 384 patients who were randomized to 
the 6-week double-blind treatment phase, 310 completed and 
283 were eligible to enter the open-label extension phase. Of 
the 283 patients, 146 (51.6%) patients completed the 46-week 
open-label extension phase. The mean daily dose of aripipra-
zole during the extension phase was 17.9 mg/day.
Continued improvement in the YMRS total score through-
out the open-label phase was noted from baseline to week 52. 
Overall reduction in MADRS score through the extension 
phase was minimal; as subjects were manic at study entry, the 
trial design is not sufficient to evaluate acute or prophylactic 
antidepressant effects.
Extrapyramidal side effects were reported in 24 (22.6%) 
of patients in the aripiprazole plus lithium group and 
38 patients (21.8%) in the aripiprazole plus valproic acid 
group. The most commonly reported EPS were tremor and 
akathisia. Minimal changes were observed on the SAS, 
AIMS or BARS. Mean change in weight from the end of 
the 6-week double-blind phase to week 46 of the open label 
phase was 2.1 kg. Median changes in total cholesterol, LDL 
cholesterol and triglycerides during the study were not clini-
cally significant.
The efficacy and safety of aripiprazole combined with 
lamotrigine was evaluated in the long-term maintenance treat-
ment of individuals with bipolar I disorder, recently manic 
or mixed.20 This two-phase study included a single-blind 
stabilization phase wherein subjects were stabilized with 
aripiprazole 10–30 mg/day + lamotrigine 100–200 mg/day. 
The stabilization period was up to 8 weeks. Individuals 
who were stabilized were randomly assigned to continue 
with aripiprazole + lamotrigine (n = 178) or lamotrigine +  
placebo (n = 173). More patients in the aripiprazole group 
(36.5%) than in the placebo (21.9%) group completed the 
study largely due to higher placebo discontinuation rate 
(31.2%) due to inefficacy. The mean dose of aripiprazole was 
18.2 mg/day. The mean dose of lamotrigine was 172 mg/day. 
The primary efficacy end-point was time from randomization 
to relapse into a manic or mixed episode operationalized as 
hospitalization, symptomatic worsening of illness and/or dis-
continuation due to inefficacy. The aripiprazole combination 
treatment arm showed a lower relapse rate when compared 
to lamotrigine monotherapy, but the result did not reach 
statistical significance. A similar finding was demonstrated 
for time to relapse to any affective episode. In the mixed 
episode subpopulation, subjects receiving aripiprazole and 
lamotrigine had a significant delay in the time to depressive 
relapse compared with placebo + lamotrigine (p = 0.041). 
During the relapse assessment phase, there were no TEAEs 
in aripiprazole treated patients occurring in 5% of subjects 
and at twice the rate of placebo. The overall mean weight 
change at the end of the double-blind phase was 0.43 kg in 
the combination group versus -1.81 kg in the lamotrigine 
monotherapy group p = 0.01.
Recently, aripiprazole was compared to placebo as an 
adjunct to lithium or valproate for the maintenance treatment 
i.e. 52 weeks in bipolar I disorder.21 Adjunctive aripiprazole 
treatment significantly delayed time to any relapse when 
compared with adjunctive placebo (hazard ratio = 0.54).   
Moreover the relapse rate for aripiprazole after 52 weeks was 
17% and 29% with placebo. The most common TEAEs were 
headache, weight increase, tremor, and insomnia.Neuropsychiatric Disease and Treatment
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Summary 
Aripiprazole is established as efficacious in the maintenance 
treatment of BD on the basis of monotherapy and adjunctive data. 
A consistent finding with aripiprazole is minimal change in body 
composition and metabolic parameters. Moreover, prolactin 
elevation is not encountered, nor is there any evidence of mood 
destabilization. Aripiprazole is associated with EPS (notably 
akathisia) which is usually mild and not treatment limiting. 
Aripiprazole has not been established as efficacious in the acute 
or maintenance treatment of bipolar depression.22 Moreover, arip-
iprazole has two negative studies in acute bipolar depression.20 
BD is usually treated with polypharmacy; combination studies 
with extended maintenance phases with lithium and possibly 
antidepressants would be interesting for future research.
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